Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 May;39(5):1972-4.
doi: 10.1128/JCM.39.5.1972-1974.2001.

Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions

S W Aberle  1 , J Kletzmayr, B Watschinger, B Schmied, N Vetter, E Puchhammer-Stöckl
Affiliations
Comparative Study

Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions

S W Aberle et al. J Clin Microbiol. 2001 May.

Abstract

A line probe assay (INNO-LiPA HBV DR) detecting drug-resistant hepatitis B virus (HBV) strains was evaluated. Results concordant with sequence analysis were obtained with 48 of 56 serum samples from HBV-infected patients undergoing lamivudine therapy. In eight cases, additional minor subpopulations could be identified by the line probe assay.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
LiPA strips 1 to 4 show the development of resistant HBV in a renal transplant patient during lamivudine therapy. Samples were taken at the beginning of therapy (strip 1), after 3 and 6 months (strips 2 and 3), and after 9 months, when a resistant strain was detectable (strip 4). LiPA strips 5 and 6 show the results of patients D and E, respectively. LiPA strip 7 shows the results found by testing an HBV DNA standard with a low copy number (103 copies/ml). Conj., conjugate; amp., amplification.
See this image and copyright information in PMC

References

    1. Allen M I, DesLauriers M, Andrews C W, Tipples G A, Walters K A, Tyrrell D L, Brown N, Condreay L D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27:1670–1677. - PubMed
    1. Allen M I, Gauthier J, DesLauriers M, Bourne E J, Carrick K M, Baldanti F, Ross L L, Lutz M W, Condreay L D. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol. 1999;37:3338–3347. - PMC - PubMed
    1. Bartholomew M M, Jansen R W, Jeffers L J, Reddy K R, Johnson L C, Bunzendahl H, Condreay L D, Tzakis A G, Schiff E R, Brown N A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997;349:20–22. - PubMed
    1. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997;26:216–225. - PubMed
    1. Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, Ng K Y, Wu P C, Dent J C, Barber J, Stephenson S L, Gray D F. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68. - PubMed

MeSH terms

LinkOut - more resources